Prostate Cancer - Results from #980

Patient Preference of Apalutamide Versus Enzalutamide for Recurrent or Metastatic Hormone-sensitive Prostate Cancer: An Open-label, Randomized, Crossover Trial. April 25, 2024

Androgen Receptor and Estrogen Receptor Variants in Prostate and Breast Cancers. April 25, 2024

Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. April 25, 2024

Identification of genes that promote PI3K pathway activation and prostate tumour formation. April 25, 2024

Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model. April 25, 2024

The Lancet Commission on prostate cancer: planning for the surge in cases. April 24, 2024

Mediator kinase inhibition reverses castration resistance of advanced prostate cancer. April 24, 2024

Overexpression of Fibroblast Activation Protein (FAP) in stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate. April 24, 2024

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer. April 24, 2024

Prostatectomy in oligometastatic prostate cancer: a call for high-quality evidence. April 24, 2024

Racial and ethnic disparities in prostate cancer screening following the 2018 US Preventive Services Task Force recommendation statement. April 24, 2024

A Systematic Review on the Impact of Quality Assurance Programs on Outcomes after Radical Prostatectomy. April 24, 2024

Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer. April 24, 2024

A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia. April 24, 2024

The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer. April 24, 2024

The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids. April 24, 2024

PGC-1α drives small cell neuroendocrine cancer progression towards an ASCL1-expressing subtype with increased mitochondrial capacity. April 24, 2024

The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. April 24, 2024

Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer. April 23, 2024

Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition. April 23, 2024

Page 50 of 1435